Racecadotril: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) recommended or restricted racecadotril, while AWMSG (Wales), SMC (Scotland) and ZIN (Netherlands) did not recommend it.
The file has been open for more than a decade: 12.1 years separate the first record, 20 Feb 2008 at HAS (France), from the most recent, 11 Mar 2020 at HAS (France).
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for racecadotril at all.
Not every gap is a refusal: for racecadotril, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2020; on this evidence the file is dormant.
4 distinct indication wordings are recorded for racecadotril by the agencies that label one in English (AWMSG and SMC).
HAS (France) was first to assess racecadotril, on 20 Feb 2008; ZIN (Netherlands) did not open a file until 17 Dec 2019 — an unusually long tail of 11.8 years between the earliest and latest system to look at it.
3 of the 4 agencies here assessed racecadotril more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed racecadotril.
The full ledger for racecadotril reads 4 not recommended, 2 recommended, 1 non-submission and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 11 Mar 2020 | Listing (Transparency Committee) | SMR moderate · ASMR V | source |
| ZIN (Netherlands) | 17 Dec 2019 | GVS-advies racecadotril (Hidrasec®) bij de behandeling van acute diarree bij zuigelingen (ouder dan 3 maanden) en kinder… | not reimbursed (GVS) | source |
| HAS (France) | 22 Jun 2016 | Listing renewal (Transparency Committee) | SMR moderate | source |
| AWMSG (Wales) | 22 Mar 2013 | Complementary symptomatic treatment of acute diarrhoea in infants (older than 3 months), and in children, together with … | not recommended (full) | source |
| SMC (Scotland) | 10 Dec 2012 | Symptomatic treatment of acute diarrhoea in adults when causal treatment is not possible | not recommended | source |
3 further decisions for racecadotril, across 3 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- teriparatide — also decided by HAS in 2020Q1
- epoetin alfa — also decided by HAS in 2020Q1
- tobramycin — also decided by HAS in 2020Q1
- bevacizumab — also decided by HAS in 2020Q1
- osimertinib — also decided by HAS in 2020Q1
- ibrutinib — also decided by HAS in 2020Q1
Coverage: 8 decisions for racecadotril from 4 agencies, 2008 to 2020. Data to 7 Sep 2026. ATC class A07X — Antidiarrheals / intestinal anti-inflammatories. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.